Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Jun;93(6):2357–2364. doi: 10.1172/JCI117241

Cellular markers that distinguish the phases of hemangioma during infancy and childhood.

K Takahashi 1, J B Mulliken 1, H P Kozakewich 1, R A Rogers 1, J Folkman 1, R A Ezekowitz 1
PMCID: PMC294441  PMID: 7911127

Abstract

Hemangiomas, localized tumors of blood vessels, appear in approximately 10-12% of Caucasian infants. These lesions are characterized by a rapid proliferation of capillaries for the first year (proliferating phase), followed by slow, inevitable, regression of the tumor over the ensuing 1-5 yr (involuting phase), and continual improvement until 6-12 yr of age (involuted phase). To delineate the clinically observed growth phases of hemangiomas at a cellular level, we undertook an immunohistochemical analysis using nine independent markers. The proliferating phase was defined by high expression of proliferating cell nuclear antigen, type IV collagenase, and vascular endothelial growth factor. Elevated expression of the tissue inhibitor of metalloproteinase, TIMP 1, an inhibitor of new blood vessel formation, was observed exclusively in the involuting phase. High expression of basic fibroblast growth factor (bFGF) and urokinase was present in the proliferating and involuting phases. There was coexpression of bFGF and endothelial phenotypic markers CD31 and von Willebrand factor in the proliferating phase. These results provide an objective basis for staging hemangiomas and may be used to evaluate pharmacological agents, such as corticosteroids and interferon alfa-2a, which accelerate regression of hemangiomas. By contrast, vascular malformations do not express proliferating cell nuclear antigen, vascular endothelial growth factor, bFGF, type IV collagenase, and urokinase. These data demonstrate immunohistochemical differences between proliferating hemangiomas and vascular malformations which reflect the biological distinctions between these vascular lesions.

Full text

PDF
2357

Images in this article

2358Image
on p.2358
2358Image
on p.2358
2358Image
on p.2358
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2360Image
on p.2360
2363Image
on p.2363
2363Image
on p.2363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli-Orlidge A., Saunders K. B., Smith S. R., D'Amore P. A. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4544–4548. doi: 10.1073/pnas.86.12.4544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartoshesky L. E., Bull M., Feingold M. Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children. Clin Pediatr (Phila) 1978 Aug;17(8):625, 629-38. doi: 10.1177/000992287801700807. [DOI] [PubMed] [Google Scholar]
  3. Bolton W. E., Mikulka W. R., Healy C. G., Schmittling R. J., Kenyon N. S. Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry. 1992;13(2):117–126. doi: 10.1002/cyto.990130203. [DOI] [PubMed] [Google Scholar]
  4. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 1992 Feb;114(2):521–532. doi: 10.1242/dev.114.2.521. [DOI] [PubMed] [Google Scholar]
  5. Burgdorf W. H., Mukai K., Rosai J. Immunohistochemical identification of factor VIII-related antigen in endothelial cells of cutaneous lesions of alleged vascular nature. Am J Clin Pathol. 1981 Feb;75(2):167–171. doi: 10.1093/ajcp/75.2.167. [DOI] [PubMed] [Google Scholar]
  6. Dethlefsen S. M., Mulliken J. B., Glowacki J. An ultrastructural study of mast cell interactions in hemangiomas. Ultrastruct Pathol. 1986;10(2):175–183. doi: 10.3109/01913128609014593. [DOI] [PubMed] [Google Scholar]
  7. Dvorak H. F., Nagy J. A., Dvorak J. T., Dvorak A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988 Oct;133(1):95–109. [PMC free article] [PubMed] [Google Scholar]
  8. Dvorak H. F., Sioussat T. M., Brown L. F., Berse B., Nagy J. A., Sotrel A., Manseau E. J., Van de Water L., Senger D. R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991 Nov 1;174(5):1275–1278. doi: 10.1084/jem.174.5.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ezekowitz R. A., Mulliken J. B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992 May 28;326(22):1456–1463. doi: 10.1056/NEJM199205283262203. [DOI] [PubMed] [Google Scholar]
  10. Folkman J., Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976;16:207–248. [PubMed] [Google Scholar]
  11. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  12. Folkman J., Klagsbrun M., Sasse J., Wadzinski M., Ingber D., Vlodavsky I. A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol. 1988 Feb;130(2):393–400. [PMC free article] [PubMed] [Google Scholar]
  13. Folkman J., Szabo S., Stovroff M., McNeil P., Li W., Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg. 1991 Oct;214(4):414–427. doi: 10.1097/00000658-199110000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974;19(0):331–358. doi: 10.1016/s0065-230x(08)60058-5. [DOI] [PubMed] [Google Scholar]
  15. Friesel R., Komoriya A., Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol. 1987 Mar;104(3):689–696. doi: 10.1083/jcb.104.3.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. GRAHAM D. P., HILL R. D. Inversion of nonpuerperal uterus. Report of a case associated with fibromyomata uteri. Obstet Gynecol. 1960 Dec;16:667–670. [PubMed] [Google Scholar]
  17. Glowacki J., Mulliken J. B. Mast cells in hemangiomas and vascular malformations. Pediatrics. 1982 Jul;70(1):48–51. [PubMed] [Google Scholar]
  18. Glukhova M. A., Frid M. G., Koteliansky V. E. Developmental changes in expression of contractile and cytoskeletal proteins in human aortic smooth muscle. J Biol Chem. 1990 Aug 5;265(22):13042–13046. [PubMed] [Google Scholar]
  19. Glukhova M. A., Frid M. G., Koteliansky V. E. Phenotypic changes of human aortic smooth muscle cells during development and in the adult vessel. Am J Physiol. 1991 Oct;261(4 Suppl):78–80. doi: 10.1152/ajpheart.1991.261.4.78. [DOI] [PubMed] [Google Scholar]
  20. Gonzalez-Crussi F., Reyes-Mugica M. Cellular hemangiomas ("hemangioendotheliomas") in infants. Light microscopic, immunohistochemical, and ultrastructural observations. Am J Surg Pathol. 1991 Aug;15(8):769–778. [PubMed] [Google Scholar]
  21. Gordon J. R., Burd P. R., Galli S. J. Mast cells as a source of multifunctional cytokines. Immunol Today. 1990 Dec;11(12):458–464. doi: 10.1016/0167-5699(90)90176-a. [DOI] [PubMed] [Google Scholar]
  22. Gospodarowicz D., Abraham J. A., Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7311–7315. doi: 10.1073/pnas.86.19.7311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. HOLMDAHL K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 1955 Jul;44(4):370–379. doi: 10.1111/j.1651-2227.1955.tb04151.x. [DOI] [PubMed] [Google Scholar]
  24. Herman I. M., D'Amore P. A. Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol. 1985 Jul;101(1):43–52. doi: 10.1083/jcb.101.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jakeman L. B., Winer J., Bennett G. L., Altar C. A., Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992 Jan;89(1):244–253. doi: 10.1172/JCI115568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kushner B. J. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Plast Reconstr Surg. 1985 Oct;76(4):517–526. doi: 10.1097/00006534-198510000-00005. [DOI] [PubMed] [Google Scholar]
  27. Kuzu I., Bicknell R., Harris A. L., Jones M., Gatter K. C., Mason D. Y. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol. 1992 Feb;45(2):143–148. doi: 10.1136/jcp.45.2.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mignatti P., Tsuboi R., Robbins E., Rifkin D. B. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol. 1989 Feb;108(2):671–682. doi: 10.1083/jcb.108.2.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Monteagudo C., Merino M. J., San-Juan J., Liotta L. A., Stetler-Stevenson W. G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990 Mar;136(3):585–592. [PMC free article] [PubMed] [Google Scholar]
  30. Montesano R., Vassalli J. D., Baird A., Guillemin R., Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7297–7301. doi: 10.1073/pnas.83.19.7297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mulliken J. B., Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982 Mar;69(3):412–422. doi: 10.1097/00006534-198203000-00002. [DOI] [PubMed] [Google Scholar]
  32. Mulliken J. B., Zetter B. R., Folkman J. In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery. 1982 Aug;92(2):348–353. [PubMed] [Google Scholar]
  33. Muthukrishnan L., Warder E., McNeil P. L. Basic fibroblast growth factor is efficiently released from a cytolsolic storage site through plasma membrane disruptions of endothelial cells. J Cell Physiol. 1991 Jul;148(1):1–16. doi: 10.1002/jcp.1041480102. [DOI] [PubMed] [Google Scholar]
  34. Naiem M., Gerdes J., Abdulaziz Z., Sunderland C. A., Allington M. J., Stein H., Mason D. Y. The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods. 1982;50(2):145–160. doi: 10.1016/0022-1759(82)90221-6. [DOI] [PubMed] [Google Scholar]
  35. Nichols G. E., Gaffey M. J., Mills S. E., Weiss L. M. Lobular capillary hemangioma. An immunohistochemical study including steroid hormone receptor status. Am J Clin Pathol. 1992 Jun;97(6):770–775. doi: 10.1093/ajcp/97.6.770. [DOI] [PubMed] [Google Scholar]
  36. Orchard P. J., Smith C. M., 3rd, Woods W. G., Day D. L., Dehner L. P., Shapiro R. Treatment of haemangioendotheliomas with alpha interferon. Lancet. 1989 Sep 2;2(8662):565–567. doi: 10.1016/s0140-6736(89)90694-6. [DOI] [PubMed] [Google Scholar]
  37. PRATT A. G. Birthmarks in infants. AMA Arch Derm Syphilol. 1953 Mar;67(3):302–305. doi: 10.1001/archderm.1953.01540030065006. [DOI] [PubMed] [Google Scholar]
  38. Pasyk K. A., Cherry G. W., Grabb W. C., Sasaki G. H. Quantitative evaluation of mast cells in cellularly dynamic and adynamic vascular malformations. Plast Reconstr Surg. 1984 Jan;73(1):69–77. doi: 10.1097/00006534-198401000-00015. [DOI] [PubMed] [Google Scholar]
  39. Pasyk K. A., Grabb W. C., Cherry G. W. Cellular haemangioma. Light and electron microscopic studies of two cases. Virchows Arch A Pathol Anat Histol. 1982;396(1):103–126. doi: 10.1007/BF00428503. [DOI] [PubMed] [Google Scholar]
  40. Pasyk K. A., Grabb W. C., Cherry G. W. Crystalloid inclusions in endothelial cells of cellular and capillary hemangiomas. A possible sign of cellular immaturity. Arch Dermatol. 1983 Feb;119(2):134–137. [PubMed] [Google Scholar]
  41. Pepper M. S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992 Dec 15;189(2):824–831. doi: 10.1016/0006-291x(92)92277-5. [DOI] [PubMed] [Google Scholar]
  42. Risau W., Sariola H., Zerwes H. G., Sasse J., Ekblom P., Kemler R., Doetschman T. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 1988 Mar;102(3):471–478. doi: 10.1242/dev.102.3.471. [DOI] [PubMed] [Google Scholar]
  43. Schulze-Osthoff K., Risau W., Vollmer E., Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol. 1990 Jul;137(1):85–92. [PMC free article] [PubMed] [Google Scholar]
  44. Senger D. R., Connolly D. T., Van de Water L., Feder J., Dvorak H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990 Mar 15;50(6):1774–1778. [PubMed] [Google Scholar]
  45. Seno M., Iwane M., Sasada R., Moriya N., Kurokawa T., Igarashi K. Monoclonal antibodies against human basic fibroblast growth factor. Hybridoma. 1989 Apr;8(2):209–221. doi: 10.1089/hyb.1989.8.209. [DOI] [PubMed] [Google Scholar]
  46. Sier C. F., Fellbaum C., Verspaget H. W., Schmitt M., Griffioen G., Graeff H., Hôfler H., Lamers C. B. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology. 1991 Sep;19(3):231–237. doi: 10.1111/j.1365-2559.1991.tb00027.x. [DOI] [PubMed] [Google Scholar]
  47. Sloan G. M., Reinisch J. F., Nichter L. S., Saber W. L., Lew K., Morwood D. T. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989 Mar;83(3):459–467. doi: 10.1097/00006534-198903000-00009. [DOI] [PubMed] [Google Scholar]
  48. Sunderkötter C., Roth J., Sorg C. Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am J Pathol. 1990 Sep;137(3):511–515. [PMC free article] [PubMed] [Google Scholar]
  49. Takigawa M., Nishida Y., Suzuki F., Kishi J., Yamashita K., Hayakawa T. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun. 1990 Sep 28;171(3):1264–1271. doi: 10.1016/0006-291x(90)90822-5. [DOI] [PubMed] [Google Scholar]
  50. Waseem N. H., Lane D. P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990 May;96(Pt 1):121–129. doi: 10.1242/jcs.96.1.121. [DOI] [PubMed] [Google Scholar]
  51. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1–8. doi: 10.1056/NEJM199101033240101. [DOI] [PubMed] [Google Scholar]
  52. White C. W., Sondheimer H. M., Crouch E. C., Wilson H., Fan L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989 May 4;320(18):1197–1200. doi: 10.1056/NEJM198905043201807. [DOI] [PubMed] [Google Scholar]
  53. White C. W., Wolf S. J., Korones D. N., Sondheimer H. M., Tosi M. F., Yu A. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991 Jan;118(1):59–66. doi: 10.1016/s0022-3476(05)81844-x. [DOI] [PubMed] [Google Scholar]
  54. Yasunaga C., Sueishi K., Ohgami H., Suita S., Kawanami T. Heterogenous expression of endothelial cell markers in infantile hemangioendothelioma. Immunohistochemical study of two solitary cases and one multiple one. Am J Clin Pathol. 1989 Jun;91(6):673–681. doi: 10.1093/ajcp/91.6.673. [DOI] [PubMed] [Google Scholar]
  55. Zetter B. R. Angiogenesis. State of the art. Chest. 1988 Mar;93(3 Suppl):159S–166S. doi: 10.1378/chest.93.3.159s. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES